Discovering Associations between Clinical Parameters and Ex-Haled Air Spectral Characteristics of COVID-19 Patients

Alexey V. Borisov
Tomsk State University, Russian Federation

Ekaterina E. Shnaider (Login required)
Tomsk State University, Russian Federation
Tomsk Phthisiopulmonology Medical Center, Russian Federation

Aleksandr S. Alliluev
Tomsk State University, Russian Federation
Tomsk Phthisiopulmonology Medical Center, Russian Federation

Yana V. Bulatova
Tomsk State University, Russian Federation

Vladimir V. Masunov
Tomsk State University, Russian Federation

Liudmila V. Spirina
Siberian State Medical University, Tomsk, Russian Federation
Tomsk National Research Medical Center, Russian Federation

Alexander P. Shkurinov
Moscow State University, Russian Federation
Institute on Laser and Information Technologies—Branch of the Federal Scientific Research Center “Crystallography and Photonics”, Russian Academy of Sciences, Shatura, Russian Federation

Yury V. Kistenev
Tomsk State University, Russian Federation


Paper #9111 received 2 Jun 2024; revised manuscript received 21 Sep 2024; accepted for publication 21 Sep 2024; published online 29 Sep 2024.

DOI: 10.18287/JBPE24.10.030305

Abstract

The associations of the exhaled air IR absorption spectra with clinical parameters characterising the state of COVID-19 patients were studied at the time of their hospitalization. The clinical parameters included standard blood tests characteristics and the presence of comorbidities. The exhaled air IR absorption spectra were measured by laser photo-acoustic gas-analyzer based on a tunable CO2 laser. The measured absorption spectra analysis was based on their splitting on subgroups in dependence on clinical parameters values and the further comparison of these subgroups with the same for healthy participants using principal component analysis. In the result, informative clinical parameters, which allowed distinguishing exhaled air absorption spectra from COVID-19 patients and healthy participants, were established. Revealed correspondence of changes in exhaled air spectral characteristics of COVID-19 patients and clinical parameters demonstrates that pathological processes occurring in the body of COVID-19 patients and success of their therapy can be revealed not only by the results of laboratory tests but also by the exhaled air spectral analysis.

Keywords

COVID-19 disease; absorption spectra of exhaled air; laser photo-acoustic spectroscopy; volatile organic compounds; principal component analysis

Full Text:

PDF SUPPL.FILE

References


1. K. Subramaniam, N. Palanisamy, R. A. Sinnaswamy, S. Muthusamy, O. P. Mishra, A. K. Loganathan, P. Ramamoorthi, C. A. R. C. Gnanakkan, G. Thangavel, and S. C. M. Sundararajan, “A comprehensive review of analyzing the chest X-ray images to detect COVID-19 infections using deep learning techniques,” Soft Computing 27(19), 14219–14240 (2023).

2. S. Grassin-Delyle, C. Roquencourt, P. Moine, G. Saffroy, S. Carn, N. Heming, J. Fleuriet, H. Salvator, E. Naline, L.-J. Couderc, P. Devillier, E. A. Thévenot, and D. Annane, “Metabolomics of exhaled breath in critically ill COVID-19 patients: A pilot study,” EBioMedicine 63, 103154 (2021).

3. A. Scholtz, A. Ramoji, A. Silge, J. R. Jansson, I. G. De Moura, J. Popp, J. P. Sram, and A. M. Armani, “COVID-19 diagnostics: past, present, and future,” ACS Photonics 8(10), 2827–2838 (2021).

4. M. Deif, R. Hammam, and A. Solyman, “Adaptive neuro-fuzzy inference system (anfis) for rapid diagnosis of covid-19 cases based on routine blood tests,” International Journal of Intelligent Engineering and Systems 14(2), 178–189 (2021).

5. I. Arpaci, S. Huang, M. Al-Emran, M. N. Al-Kabi, and M. Peng, “Predicting the COVID-19 infection with fourteen clinical features using machine learning classification algorithms,” Multimed Tools and Application 80(8), 11943–11957 (2021).

6. L. Falzone, G. Gattuso, A. Tsatsakis, D. Spandidos, and M. Libra, “Current and innovative methods for the diagnosis of COVID‑19 infection (Review),” International Journal of Molecular Medicine 47(6), 100 (2021).

7. A. Bedair, K. Okasha, and F. R. Mansour, “Spectroscopic methods for COVID-19 detection and early diagnosis,” Virology Journal 19(1), 152 (2022).

8. Y. V. Kistenev, D. A. Vrazhnov, E. E. Shnaider, and H. Zuhayri, “Predictive models for COVID-19 detection using routine blood tests and machine learning,” Heliyon 8(10), e11185 (2022).

9. M. Kukar, G. Gunčar, T. Vovko, S. Podnar, P. Černelč, M. Brvar, M. Zalaznik, M. Notar, S. Moškon, and M. Notar, “COVID-19 diagnosis by routine blood tests using machine learning,” Scientific Reports 11(1), 10738 (2021).

10. M. Lagadinou, E. E. Solomou, N. Zareifopoulos, M. Marangos, C. Gogos, and D. Velissaris, “Prognosis of COVID-19: Changes in laboratory parameters,” Le Infezioni in Medicina 28(Suppl. 1), 89−95 (2020).

11. L. L. Fernandes, V. B. Pacheco, L. Borges, H. K. Athwal, F. De Paula Eduardo, L. Bezinelli, L. Correa, M. Jimenez, N. Dame-Teixeira, I. M. A. Lombaert, and D. Heller, “Saliva in the Diagnosis of COVID-19: A Review and New Research Directions,” Journal of Dental Research 99(13), 1435–1443 (2020).

12. R. Liu, Q. Ma, H. Han, H. Su, F. Liu, K. Wu, W. Wang, and C. Zhu, “The value of urine biochemical parameters in the prediction of the severity of coronavirus disease 2019,” Clinical Chemistry and Laboratory Medicine (CCLM) 58(7), 1121–1124 (2020).

13. B. N. Zamora-Mendoza, L. Díaz De León-Martínez, M. Rodríguez-Aguilar, B. Mizaikoff, and R. Flores-Ramírez, “Chemometric analysis of the global pattern of volatile organic compounds in the exhaled breath of patients with COVID-19, post-COVID and healthy subjects. Proof of concept for post-COVID assessment,” Talanta 236, 122832 (2022).

14. M. Woollam, P. Angarita-Rivera, A. P. Siegel, V. Kalra, R. Kapoor, and M. Agarwal, “Exhaled VOCs can discriminate subjects with COVID-19 from healthy controls,” Journal of Breath Research 16(3), 036002 (2022).

15. S. Grassin-Delyle, C. Roquencourt, P. Moine, G. Saffroy, S. Carn, N. Heming, J. Fleuriet, H. Salvator, E. Naline, L.-J. Couderc, P. Devillier, E. A. Thévenot, and D. Annane, “Metabolomics of exhaled breath in critically ill COVID-19 patients: A pilot study,” EBioMedicine 63, 103154 (2021).

16. A. Liangou, A. Tasoglou, H. J. Huber, C. Wistrom, K. Brody, P. G. Menon, T. Bebekoski, K. Menschel, M. Davidson-Fiedler, K. DeMarco, H. Salphale, J. Wistrom, S. Wistrom, and R. J. Lee, “A method for the identification of COVID-19 biomarkers in human breath using Proton Transfer Reaction Time-of-Flight Mass Spectrometry,” eClinicalMedicine 42, 101207 (2021).

17. H. Chen, X. Qi, L. Zhang, X. Li, J. Ma, C. Zhang, H. Feng, and M. Yao, “COVID-19 screening using breath-borne volatile organic compounds,” Journal of Breath Research 15, 047104 (2021).

18. W. Ibrahim, R. L. Cordell, M. J. Wilde, M. Richardson, L. Carr, A. Sundari Devi Dasi, B. Hargadon, R. C. Free, P. S. Monks, C. E. Brightling, N. J. Greening, and S. Siddiqui, “Diagnosis of COVID-19 by exhaled breath analysis using gas chromatography–mass spectrometry,” ERJ Open Research 7(3), 00139–02021 (2021).

19. L. Kurver, C. H. Van Den Kieboom, K. Lanke, D. A. Diavatopoulos, G. J. Overheul, M. G. Netea, J. Ten Oever, R. Van Crevel, K. Mulders-Manders, F. L. Van De Veerdonk, H. Wertheim, J. Schouten, J. Rahamat-Langendoen, R. P. Van Rij, T. Bousema, A. Van Laarhoven, and M. I. De Jonge, “SARS-CoV-2 RNA in exhaled air of hospitalized COVID-19 patients,” Scientific Reports 12(1), 8991 (2022).

20. H. Malá, Z. Zadák, L. Sobotka, and J. Malý, “Changes in selected biochemical parameters during a low-calorie reducing diet,” Sbornik Lekarsky 101(1), 105−108 (2000).

21. C. M. Pariante, B. Carpiniello, G. Orrù, R. Sitzia, A. Piras, G. Farci, S. Del Giacco, G. Piludu, and A. H. Miller, “Chronic Caregiving Stress Alters Peripheral Blood Immune Parameters: The Role of Age and Severity of Stress,” Psychother Psychosom 66(4), 199–207 (1997).

22. W. Filipiak, V. Ruzsanyi, P. Mochalski, A. Filipiak, A. Bajtarevic, C. Ager, H. Denz, W. Hilbe, H. Jamnig, M. Hackl, A. Dzien, and A. Amann, “Dependence of exhaled breath composition on exogenous factors, smoking habits and exposure to air pollutants,” Journal of Breath Research 6(3), 036008 (2012).

23. S. Traxler, G. Barkowsky, R. Saß, A.-C. Klemenz, N. Patenge, B. Kreikemeyer, J. K. Schubert, and W. Miekisch, “Volatile scents of influenza A and S. pyogenes (co-)infected cells,” Scientific Reports 9(1), 18894 (2019).

24. Y. V. Kistenev, A. I. Karapuzikov, N. Yu. Kostyukova, M. K. Starikova, A. A. Boyko, E. B. Bukreeva, A. A. Bulanova, D. B. Kolker, D. A. Kuzmin, K. G. Zenov, and A. A. Karapuzikov, “Screening of patients with bronchopulmonary diseases using methods of infrared laser photoacoustic spectroscopy and principal component analysis,” Journal of Biomedical Optics 20(6), 065001 (2015).

25. J. Dummer, M. Storer, M. Swanney, M. McEwan, A. Scott-Thomas, S. Bhandari, S. Chambers, R. Dweik, and M. Epton, “Analysis of biogenic volatile organic compounds in human health and disease,” TrAC Trends in Analytical Chemistry 30(7), 960–967 (2011).

26. M. Metsälä, “Optical techniques for breath analysis: from single to multi-species detection,” Journal of Breath Research 12(2), 027104 (2018).

27. M. J. Navas, A. M. Jiménez, and A. G. Asuero, “Human biomarkers in breath by photoacoustic spectroscopy,” Clinica Chimica Acta 413(15–16), 1171–1178 (2012).

28. W. Guan, Z. Ni, Y. Hu, W. Liang, C. Ou, J. He, L. Liu, H. Shan, C. Lei, D. S. C. Hui, B. Du, L. Li, G. Zeng, K.-Y. Yuen, R. Chen, C. Tang, T. Wang, P. Chen, J. Xiang, S. Li, J. Wang, Z. Liang, Y. Peng, L. Wei, Y. Liu, Y. Hu, P. Peng, J. Wang, J. Liu, Z. Chen, G. Li, Z. Zheng, S. Qiu, J. Luo, C. Ye, S. Zhu, and N. Zhong, “Clinical characteristics of coronavirus disease 2019 in china,” New England Journal of Medicine 382(18), 1708–1720 (2020).

29. T. Guo, Q. Shen, W. Guo, W. He, J. Li, Y. Zhang, Y. Wang, Z. Zhou, D. Deng, X. Ouyang, Z. Xiang, M. Jiang, M. Liang, P. Huang, Z. Peng, X. Xiang, W. Liu, H. Luo, P. Chen, and H. Peng, “Clinical characteristics of elderly patients with covid-19 in hunan province, china: a multicenter, retrospective study,” Gerontology 66(5), 467–475 (2020).

30. L. Bitker, F. Dhelft, L. Chauvelot, E. Frobert, L. Folliet, M. Mezidi, S. Trouillet-Assant, A. Belot, B. Lina, F. Wallet, and J. C. Richard, “Protracted viral shedding and viral load are associated with ICU mortality in Covid-19 patients with acute respiratory failure,” Annals of Intensive Care 10(1), 167 (2020).

31. S. Drefahl, M. Wallace, E. Mussino, S. Aradhya, M. Kolk, M. Brandén, B. Malmberg, and G. Andersson, “A population-based cohort study of socio-demographic risk factors for COVID-19 deaths in Sweden,” Nature Communications 11(1), 5097 (2020).

32. W. Guo, M. Li, Y. Dong, H. Zhou, Z. Zhang, C. Tian, R. Qin, H. Wang, Y. Shen, K. Du, L. Zhao, H. Fan, S. Luo, and D. Hu, “Diabetes is a risk factor for the progression and prognosis of COVID ‐19,” Diabetes/Metabolism Research and Reviews 36(7), e3319 (2020).

33. M. R. Alam, Md. R. Kabir, and S. Reza, “Comorbidities might be a risk factor for the incidence of COVID-19: Evidence from a web-based survey,” Preventive Medicine Reports 21, 101319 (2021).

34. B. G. Ageev, V. A. Kapitanov, Yu. N. Ponomarev, O. Yu. Nikiforova, A. I. Karapuzikov, I. V. Sherstov, L. I. Volkova, E. Yu. Djakova, L. V. Kapilevich, D. V. Kapitanova, Yu. V. Kistenev, N. A. Smotrova, V. A. Fokin, A. V. Plohotin, and T. A. Berendeeva, “Photoacoustic spectroscopy of the expired air at a human respiratory pathology,” 6580, 176–182 (2006).

35. D. Armbruster, R. R. Miller, “The Joint Committee for Traceability in Laboratory Medicine (JCTLM): A Global Approach to Promote the Standardisation of Clinical Laboratory Test Results,” Clinical Biochemist Reviews 28(3), 105 (2007).

36. M. Panteghini, F. Braga, J. E. Camara, V. Delatour, K. Van Uytfanghe, H. W. Vesper, T. Zhang, and for the JCTLM Task Force on Reference Measurement System Implementation, “Optimizing available tools for achieving result standardization: value added by joint committee on traceability in laboratory medicine (JCTLM),” Clinical Chemistry 67(12), 1590–1605 (2021).

37. D. Groth, S. Hartmann, S. Klie, and J. Selbig, “Principal components analysis,” Computational Toxicology 930, 527–547 (2013).

38. Z. Gniazdowski, “New interpretation of principal components analysis,” Zeszyty Naukowe WWSI 11(16), 43–65 (2017).

39. N. Salem, S. Hussein, “Data dimensional reduction and principal components analysis,” Procedia Computer Science 163, 292–299 (2019).

40. G. Li, Y. Yang, D. Gao, Y. Xu, J. Gu, and P. Liu, “Is liver involvement overestimated in COVID-19 patients? A meta-analysis,” International Journal of Medical Sciences 18(5), 1285–1296 (2021).

41. P. Malik, U. Patel, D. Mehta, N. Patel, R. Kelkar, M. Akrmah, J. L. Gabrilove, and H. Sacks, “Biomarkers and outcomes of COVID-19 hospitalisations: systematic review and meta-analysis,” BMJ Evidence-Based Medicine 26(3), 107–108 (2021).

42. Y. Wang, L. Shi, Y. Wang, and H. Yang, “An updated meta-analysis of AST and ALT levels and the mortality of COVID-19 patients,” The American Journal of Emergency Medicine 40, 208–209 (2021).

43. U. Boregowda, M. M. Aloysius, A. Perisetti, M. Gajendran, P. Bansal, and H. Goyal, “Serum Activity of Liver Enzymes Is Associated With Higher Mortality in COVID-19: A Systematic Review and Meta-Analysis,” Frontiers in Medicine 7, 431 (2020).

44. M. Panteghini, “Aspartate aminotransferase isoenzymes,” Clinical Biochemistry 23(4), 311–319 (1990).

45. Z. Liu, S. Que, J. Xu, and T. Peng, “Alanine Aminotransferase-Old Biomarker and New Concept: A Review,” International Journal of Medical Sciences 11(9), 925–935 (2014).

46. H. M. Al-kuraishy, A. I. Al-Gareeb, A. Kaushik, M. Kujawska, and G. E.-S. Batiha, “Hemolytic anemia in COVID-19,” Annals of Hematology 101(9), 1887–1895 (2022).

47. D. Jothimani, R. Venugopal, M. F. Abedin, I. Kaliamoorthy, and M. Rela, “COVID-19 and the liver,” Journal of Hepatology 73(5), 1231–1240 (2020).

48. M. R. Thomas, M. Scully, “Clinical features of thrombosis and bleeding in COVID-19,” Blood 140(3), 184–195 (2022).

49. D. McGonagle, J. S. O’Donnell, K. Sharif, P. Emery, and C. Bridgewood, “Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia,” The Lancet Rheumatology 2(7), e437–e445 (2020).

50. M. Levi, J. Thachil, T. Iba, and J. H. Levy, “Coagulation abnormalities and thrombosis in patients with COVID-19,” The Lancet Haematology 7(6), e438–e440 (2020).

51. H. Al-Samkari, R. S. Karp Leaf, W. H. Dzik, J. C. T. Carlson, A. E. Fogerty, A. Waheed, K. Goodarzi, P. K. Bendapudi, L. Bornikova, S. Gupta, D. E. Leaf, D. J. Kuter, and R. P. Rosovsky, “COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection,” Blood 136(4), 489–500 (2020).

52. X. Yuan, W. Huang, B. Ye, C. Chen, R. Huang, F. Wu, Q. Wei, W. Zhang, and J. Hu, “Changes of hematological and immunological parameters in COVID-19 patients,” International Journal of Hematology 112(4), 553–559 (2020).

53. J. Sui, D. F. Noubouossie, S. Gandotra, and L. Cao, “Elevated Plasma Fibrinogen Is Associated With Excessive Inflammation and Disease Severity in COVID-19 Patients,” Frontiers in Cellular and Infection Microbiology 11, 734005 (2021).

54. P. Di Micco, V. Russo, N. Carannante, M. Imparato, G. Cardillo, and C. Lodigiani, “Prognostic value of fibrinogen among covid-19 patients admitted to an emergency department: an italian cohort study,” Journal of Clinical Medicine 9(12), 4134 (2020).

55. S. A. Mousavi, S. Rad, T. Rostami, M. Rostami, S. A. Mousavi, S. A. Mirhoseini, and A. Kiumarsi, “Hematologic predictors of mortality in hospitalized patients with COVID-19: a comparative study,” Hematology 25(1), 383–388 (2020).

56. P. E. Taneri, S. A. Gómez-Ochoa, E. Llanaj, P. F. Raguindin, L. Z. Rojas, Z. M. Roa-Díaz, D. Salvador, D. Groothof, B. Minder, D. Kopp-Heim, W. E. Hautz, M. F. Eisenga, O. H. Franco, M. Glisic, and T. Muka, “Anemia and iron metabolism in COVID-19: a systematic review and meta-analysis,” European Journal of Epidemiology 35(8), 763–773 (2020).

57. T. Iba, J. H. Levy, M. Levi, J. M. Connors, and J. Thachil, “Coagulopathy of Coronavirus Disease 2019,” Critical Care Medicine 48(9), 1358–1364 (2020).

58. A. W. DeMartino, J. J. Rose, M. B. Amdahl, M. R. Dent, F. A. Shah, W. Bain, B. J. McVerry, G. D. Kitsios, J. Tejero, and M. T. Gladwin, “No evidence of hemoglobin damage by SARS-CoV-2 infection,” Haematologica 105(12), 2769–2773 (2020).

59. A. Zinellu, P. Paliogiannis, C. Carru, and A. A. Mangoni, “INR and COVID-19 severity and mortality: A systematic review with meta-analysis and meta-regression,” Advances in Medical Sciences 66(2), 372–380 (2021)

60. I. E. Irgashev, “New Principles of Anticoagulant Therapy in Patients with Covid-19,” Research Journal of Trauma and Disability Studies 1(12), 15–19 (2022).

61. A. Teimury, M. T. Khameneh, and E. M. Khaledi, “Major coagulation disorders and parameters in COVID-19 patients,” European Journal of Medical Research 27(1), 25 (2022).

62. T. Jiang, B. Lv, H. Liu, S. He, G. Zhang, C. Li, W. Li, W. Li, Y. He, T. Zhang, Y. Wang, W. Mo, N. Yi, L. Peng, Y. Li, C. Ruan, C. Li, Y. Liu, P. Luo, H. Jiang, Z. Xue, L. Liu, and W. Wang, “Autopsy and statistical evidence of disturbed hemostasis progress in COVID-19: medical records from 407 patients,” Thrombosis Journal 19(1), 8 (2021).

63. E. Tekle, Y. Gelaw, M. Dagnew, A. Gelaw, M. Negash, E. Kassa, S. Bizuneh, D. Wudineh, and F. Asrie, “Risk stratification and prognostic value of prothrombin time and activated partial thromboplastin time among COVID-19 patients,” PLoS ONE 17(8), e0272216 (2022).

64. D. Liao, F. Zhou, L. Luo, M. Xu, H. Wang, J. Xia, Y. Gao, L. Cai, Z. Wang, P. Yin, Y. Wang, L. Tang, J. Deng, H. Mei, and Y. Hu, “Haematological characteristics and risk factors in the classification and prognosis evaluation of COVID-19: a retrospective cohort study,” The Lancet Haematology 7(9), e671–e678 (2020).

65. B. Gallo Marin, G. Aghagoli, K. Lavine, L. Yang, E. J. Siff, S. S. Chiang, T. P. Salazar‐Mather, L. Dumenco, M. C. Savaria, S. N. Aung, T. Flanigan, and I. C. Michelow, “Predictors of COVID ‐19 severity: A literature review,” Reviews in Medical Virology 31(1), 1–10 (2021).

66. J. T. Busher, “Serum Albumin and Globulin,” Chapter 101 in Clinical Methods: The History, Physical, and Laboratory Examinations, H. K. Walker, W. D. Hall, and J. W. Hurst, 3rd Ed., Butterworths, Boston (1990).

67. R. K. Saini, N. Saini, S. Ram, S. L. Soni, V. Suri, P. Malhotra, J. Kaur, I. Verma, S. Sharma, and D. Zohmangaihi, “COVID-19 associated variations in liver function parameters: a retrospective study,” Postgraduate Medical Journal 98(1156), 91–97 (2022).

68. X. Han and Q. Ye, “Kidney involvement in COVID‐19 and its treatments,” Journal of Medical Virology 93(3), 1387–1395 (2021).

69. B. M. Kagan, “Studies on the clinical significance of the serum proteins: ii. the relationship between the albumin-globulin ratio, albumin, globulin and total protein,” Archives of Internal Medicine (Chic) 71(2), 157 (1943).

70. G. Wu, P. Yang, Y. Xie, H. C. Woodruff, X. Rao, J. Guiot, A.-N. Frix, R. Louis, M. Moutschen, J. Li, J. Li, C. Yan, D. Du, S. Zhao, Y. Ding, B. Liu, W. Sun, F. Albarello, A. D’Abramo, V. Schininà, E. Nicastri, M. Occhipinti, G. Barisione, E. Barisione, I. Halilaj, P. Lovinfosse, X. Wang, J. Wu, and P. Lambin, “Development of a Clinical Decision Support System for Severity Risk Prediction and Triage of COVID-19 Patients at Hospital Admission: an International Multicenter Study,” European Respiratory Journal 2001104 (2020).

71. X. Li, S. Xu, M. Yu, K. Wang, Y. Tao, Y. Zhou, J. Shi, M. Zhou, B. Wu, Z. Yang, C. Zhang, J. Yue, Z. Zhang, H. Renz, X. Liu, J. Xie, M. Xie, and J. Zhao, “Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan,” Journal of Allergy and Clinical Immunology 146(1), 110–118 (2020).

72. R. Pranata, M. A. Lim, I. Huang, S. B. Raharjo, and A. A. Lukito, “Hypertension is associated with increased mortality and severity of disease in COVID-19 pneumonia: A systematic review, meta-analysis and meta-regression,” Journal of the Renin-Angiotensin-Aldosterone System 21(2), 147032032092689 (2020).

73. M. Peng, J. He, Y. Xue, X. Yang, S. Liu, and Z. Gong, “Role of Hypertension on the Severity of COVID-19: A Review,” Journal of Cardiovascular Pharmacology 78(5), e648–e655 (2021).

74. M. R. Mehra, S. S. Desai, S. Kuy, T. D. Henry, and A. N. Patel, “Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19,” The New England Journal of Medicine 382(25), (2020).

75. K. Nielsen Jeschke, B. Bonnesen, E. F. Hansen, J.-U. S. Jensen, T. S. Lapperre, U. M. Weinreich, and O. Hilberg, “Guideline for the management of COVID-19 patients during hospital admission in a non-intensive care setting,” European Clinical Respiratory Journal 7(1), 1761677 (2020).

76. S. A. Kharitonov, P. J. Barnes, “Exhaled Biomarkers,“ Chest 130(5), 1541–1546 (2006).

77. S. A. Kharitonov, A. U. Wells, B. J. O’Connor, P. J. Cole, D. M. Hansell, R. B. Logan-Sinclair, and P. J. Barnes, “Elevated levels of exhaled nitric oxide in bronchiectasis,” American Journal of Respiratory and Critical Care Medicine 151(6), 1889–1893 (1995).

78. M. Ejazi, M. Shameem, R. Bhargava, Z. Ahmad, J. Akhtar, N. Khan, M. Alam, M. Alam, and C. Adil Wafi, “Correlation of exhaled carbon monoxide level with disease severity in chronic obstruction pulmonary disease,” Lung India 35(5), 401 (2018).

79. P. D. Wagner, “The physiological basis of pulmonary gas exchange: implications for clinical interpretation of arterial blood gases,” European Respiratory Journal 45(1), 227–243 (2015).

80. R. A. Klocke, “Velocity of CO 2 Exchange in Blood,” Annual Review of Physiology 50(1), 625–637 (1988).




Bookmark and Share


Сontact

34 Moskovskoe shosse, Samara, 443086, Russian Federation
Email: j-bpe@ssau.ru
Phone: +7-846-267-4550
© 2014-2025 J-BPE